Sobi has been named one of the World’s Most Impactful Companies 2026 by TIME and Statista — a recognition that celebrates organisations driving meaningful change for people and the planet.
The ranking highlights 500 companies that work to address high-priority global challenges as part of their core business — proof that companies can do good and do well. Each company is assessed on how much positive or negative impact it has on areas like human physical and mental health, knowledge, and the environment.
For Sobi, impact is not a destination but a continuous journey. Every step forward reflects our commitment to transforming everyday life for people living with rare diseases through innovation, access, and collaboration. This recognition follows Sobi’s inclusion in the Dow Jones Best-in-Class (DJ BIC) Indices, highlighting our ongoing commitment to sustainability and responsible business practices.
“We are honoured to be included among companies recognised for their global impact,” said Cecilia Nord, Global Head of Sustainability. “This achievement belongs to our employees and partners who work every day to turn our purpose into progress for the rare disease community.”
This recognition underscores the growing importance of purpose-driven healthcare and the role companies can play in creating sustainable, long-term value for society.
We thank our employees and partners, and the rare disease community for making this recognition possible — and for inspiring us to keep moving forward.
Read the full TIME and Statista ranking here.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Here we present our most recent press releases, stories, news articles, and images.
Find out more about our business and financial performance.
Every day, we work actively to find better ways to understand and meet patient needs.